Systematic review of semaglutide for HFpEF in obese patients: consistent symptom improvement but mortality data pending | Research

The takeaway

Systematic review of semaglutide vs placebo in obese HFpEF confirms consistent improvements in symptoms, functional capacity, quality of life, and weight, but notes insufficient data on mortality and hospitalization endpoints.

Symptoms yes, survival unknown
Semaglutide consistently improves obese HFpEF symptoms and function, but the key question—does it prevent death and hospitalization?—awaits larger outcome trials

What the researchers found

Semaglutide vs placebo in obese HFpEF: consistently improved symptoms, functional capacity, QoL, and weight. Insufficient evidence: mortality and HF hospitalization endpoints. Need: larger event-driven outcome trials.

Why it matters

While symptom improvement is meaningful for patients, regulatory approval and guideline inclusion for HFpEF require mortality/hospitalization data. This review precisely defines what we know and what gaps remain.

How the study worked

Systematic review of RCTs comparing semaglutide vs placebo in obese HFpEF.

What this study cannot tell us

Systematic review of available trials. Hard endpoint data insufficient. Short trial durations for mortality outcomes. Specific effect sizes not in abstract preview.

How to read the evidence

Systematic review of RCTs. Strong for symptom outcomes. Insufficient for hard endpoints.

When this study was published

Published in 2025.

The bigger picture

Semaglutide clearly helps obese HFpEF patients feel and function better. The remaining question—does it prevent death and hospitalization?—will determine whether it becomes standard of care.

Questions still open

When will semaglutide HFpEF outcome trials report?
Are symptom improvements sufficient for a HFpEF indication?
Would combining semaglutide with SGLT2i improve hard outcomes?

Common questions

Does semaglutide help with heart failure?

For symptoms—clearly yes. This systematic review shows semaglutide consistently improves how HFpEF patients feel and function: better symptom control, more exercise capacity, better quality of life. However, whether it actually prevents heart failure hospitalizations or death has not yet been proven in large enough trials.

Should HFpEF patients take semaglutide?

For obese HFpEF patients, semaglutide offers meaningful symptom improvement and weight loss. However, it does not yet have a formal heart failure indication because large trials testing whether it prevents death and hospitalizations are still ongoing. Current prescribing would be primarily for diabetes or obesity with HFpEF benefit as an added advantage.

Read the original research

Effect of Semaglutide Versus Placebo on Heart Failure With Preserved Ejection Fraction in Obese Patients: A Systematic Review.

Cureus, 17(6), e85250

View on PubMed ↗Publisher’s paper ↗

Citation

Umaña Mejia, Carlos Alberto; Sañudo Soto, Claudia Victoria; Robalino, Juan; Hernández, Mayra; Santos Bretón, Myriam Bertha; Garcia-Vasquez, Edwin A; Rocha, Paola; Palacios Brambila, Luis Miguel; Morales, Sergio; Romo, Miguel; Castillo, Jaqueline L; Montelongo Quevedo, Mauricio; Flores Valdés, Jose R. (2025). Effect of Semaglutide Versus Placebo on Heart Failure With Preserved Ejection Fraction in Obese Patients: A Systematic Review.. Cureus, 17(6), e85250. https://doi.org/10.7759/cureus.85250